Disarm Therapeutics (United States)

Alternate names: Disarm Therapeutics, Disarm Therapeutics, Inc.

Parent institution: Eli Lilly (United States)

ROR: 058hwgk11

OpenAlex ID: I4405282047

NAD + cleavage activity by animal and plant TIR domains in cell death pathways

2019 · Shane Horsefield, Hayden Burdett, et al. · Science · 488

SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration

2021 · Matthew D. Figley, Weixi Gu, et al. · Neuron · 341

Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate

2021 · Robert O. Hughes, Todd Bosanac, et al. · Cell Reports · 187

Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy

2021 · Todd Bosanac, Robert O Hughes, et al. · Brain · 154

Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules

2022 · Yun Shi, Philip S. Kerry, et al. · Molecular Cell · 145

Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration

2020 · Raul Krauss, Todd Bosanac, et al. · Trends in Pharmacological Sciences · 129

cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons

2020 · Yo Sasaki, Thomas M. Engber, et al. · Experimental Neurology · 113

Role of a Contactin multi‐molecular complex secreted by oligodendrocytes in nodal protein clustering in the CNS

2019 · Anne‐Laure Dubessy, Elisa Mazuir, et al. · Glia · 40

Crystal and cryo-EM structures provide insight into how pro-neurodegenerative SARM1 is activated and cleaves NAD+

2021 · Thomas Ve, Weixi Gu, et al. · Acta Crystallographica Section A Foundations and Advances

SARM1 Loss of Function in Chronic and Acute CNS Axonopathies (P1.2-085)

2019 · Raul Krauss, Robert Hughes, et al. · Neurology

Works count: 10

Citation count: 5,048